{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

3_Medicalization of Race - Duster

3_Medicalization of Race - Duster - Essay Focus The...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
Essay Focus 704 www.thelancet.com Vol 369 February 24, 2007 The appearance of racialised drugs on pharmacists’ shelves only increases the need to attend to the myriad social sources of disparities in morbidity and mortality. Although to turn a profit from fighting racial discrimination is diffi cult, effective medical care demands continued awareness of the complex social dimensions of diseases, such as hypertension and cancer. Conflict of interest statement I declare that I have no conflict of interest. References 1 Financial Times (London) , March 9, 2001: 16. 2 Cohn J N. The Vasodilator-Heart Failure Trials (V-HeFT): mechanistic data from the VA Cooperative Studies. Circulation 1993: 87 (suppl 6 ) : V 1–2. 3 Kahn J. How a drug becomes ‘ethnic’: law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004; 4: 1–46. 4 NitroMed. Press Release: NitroMed receives FDA letter on BiDil NDA, a treatment for heart failure in black patients. March 8, 2001. 5 Food and Drug Administration. FDA approves BiDil heart failure drug for black patients. June 23, 2005: http://www.fda.gov/bbs/ topics/NEWS/2005/NEW01190.html (accessed Dec 4, 2006). 6 Kahn, J. Misreading race and genomics after BiDil. Nat Genet 2005; 37: 655–56. 7 Taylor AL, Ziesche S, Yancy C, et al, for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–57.
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}